Servier to buy Day One Biopharmaceuticals in $2.5B deal

French pharmaceutical group Servier has agreed to buy cancer therapy biotech Day One Biopharmaceuticals (NASDAQ: DAWN) in a $2.5 billion deal.

Why it matters: Day One's assets in market and in development will bolster Servier's offerings in rare oncology.